scholarly journals Clinical impact of postoperative interval until adjuvant chemotherapy following curative gastrectomy for advanced gastric cancer

2021 ◽  
Vol 12 (19) ◽  
pp. 5960-5966
Author(s):  
Yusuke Takashima ◽  
Shuhei Komatsu ◽  
Keiji Nishibeppu ◽  
Jun Kiuchi ◽  
Takuma Ohashi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Advanced Gastric Cancer ◽  
Clinical Impact ◽  
Curative Gastrectomy ◽  
Postoperative Interval

scholarly journals Clinical Impact of Clinicopathological Characteristics of Undifferentiated Advanced Gastric Cancer in Elderly Patients

2020 ◽  
pp. 1-7
Author(s):  
Norio Shiraishi ◽  
Hajime Fujishima ◽  
Hidefumi Shiroshita ◽  
Masafumi Inomata ◽  
Norio Shiraishi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Elderly Patients ◽  
Advanced Gastric Cancer ◽  
Median Number ◽  
Clinicopathological Characteristics ◽  
Clinical Impact ◽  
Curative Gastrectomy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Clinicopathological Findings

Background: Little is known about the clinicopathological findings in elderly patients with undifferentiated advanced gastric cancer. The aim of this study was to clarify the clinical impact of clinicopathological characteristics of those cancers in elderly patients. Method: A total of 42 patients aged 80 years or older with advanced gastric cancer who had undergone curative gastrectomy between 1998 and 2015 were included in this study. All patients were classified into two principal subgroups based on histology: undifferentiated group and differentiated group. The two groups were examined and compared with respect to the pathological findings and clinical outcomes. Results: Of the 47 patients, 23 (49%) patients were in the undifferentiated group and 24 (51%) were in the differentiated group. The undifferentiated cancer was less frequently located in the upper third of the stomach than the differentiated cancer (4% vs 42%, P < 0.01). The frequency of the cancer with depth of T4a was higher in the undifferentiated group than in the differentiated group (48% vs. 17%, P < 0.05). The median number of metastatic lymph nodes in the undifferentiated group was more than that in the differentiated group (3 vs. 1, P < 0.05). In short- and long-term outcome after curative gastrectomy, there were no differences between the two groups. Conclusion: In elderly patients, undifferentiated advanced gastric cancer may have more malignant potential than differentiated cancer. However, by curative gastrectomy, the elderly patients with undifferentiated advanced gastric cancer can be obtained the equivalent clinical outcome to those with differentiated cancer.

Pre-adjuvant chemotherapy leukocyte count may predict the outcome for advanced gastric cancer after radical resection

2014 ◽  
Vol 68 (2) ◽  
pp. 213-217 ◽  
Author(s):  
Dong Pei ◽  
Fang Zhu ◽  
Xiaofeng Chen ◽  
Jing Qian ◽  
Shaohua He ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Advanced Gastric Cancer ◽  
Leukocyte Count ◽  
Radical Resection

Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study

2021 ◽  
pp. 20201088
Author(s):  
Fuli Wang ◽  
Aizhong Qu ◽  
Yinping Sun ◽  
Jifeng Zhang ◽  
Benzun Wei ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Postoperative Complications ◽  
Advanced Gastric Cancer ◽  
Neoadjuvant Chemoradiotherapy ◽  
Regional Recurrence ◽  
R0 Resection ◽  
Resection Rate ◽  
Postoperative Adjuvant Chemotherapy ◽  
Local Advanced

Objective: The aim of this study was to compare the clinical efficacy of neoadjuvant chemoradiotherapy (NACRT) combined with postoperative adjuvant XELOX (Oxaliplatin +Capecitabine) chemotherapy and postoperative adjuvant chemotherapy (ACT) with XELOX for local advanced gastric cancer (LAGC). Methods: In this prospectively randomized trial, we investigated the effect of NACRT combined with postoperative ACT for LAGC. 60 patients were randomly divided into NACRT group and ACT group, with 30 patients in each group. Patients in NACRT group were given three-dimensional conformal radiotherapy (45 Gy/1.8 Gy/f) accompanied by synchronous XELOX of two cycles, followed by surgery, and then postoperative adjuvant XELOX chemotherapy of four cycles was performed. Patients in ACT group received surgery in advance, and then XELOX chemotherapy of six cycles was given. Results: The objective response rate of NACRT was 76.7%. The overall incidence of postoperative complications in NACRT group was not significantly different from that in ACT group (23.1% vs 30.0%, p = 0.560). The 1 year, 2 years, and 3 years progression-free survival (PFS）and overall survival (OS) in NACRT and ACT groups were 80.0% vs 56.7%, 73.3% vs 46.7%, 60.0% vs 33.3%, and 86.7% vs 80.0%, 76.7% vs 66.7%, 63.3% vs 50.0%, respectively. Patients in NACRT group showed a significantly higher R0 resection rate (84.6% vs 56.7%, p = 0.029),lower loco-regional recurrence rate (36.7% vs 11.5%, p = 0.039), longer PFS (p = 0.019) and freedom from locoregional progression(FFLP) (p = 0.004) than patients in ACT group, while there was no difference in OS (p = 0.215) and in toxicity incidence (p > 0.05). Conclusions: NACRT combined with postoperative adjuvant XELOX chemotherapy can improve R0 resection rate, reduce loco-regional recurrence, prolong PFS and FFLP without increasing the incidence of postoperative complications in patients with LAGC. Advances in knowledge: Compared with postoperative adjuvant chemotherapy, locally advanced gastric cancer patients may benefit from neoadjuvant chemoradiotherapy, and toxicity associated with chemoradiotherapy was tolerant and manageable.

Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy

2014 ◽  
Vol 14 (5) ◽  
pp. 418-423 ◽  
Author(s):  
F Graziano ◽  
V Catalano ◽  
P Lorenzini ◽  
E Giacomini ◽  
D Sarti ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Palliative Chemotherapy ◽  
Clinical Impact ◽  
Pathway Activation

Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection

1990 ◽  
Vol 45 (3) ◽  
pp. 169-172 ◽  
Author(s):  
Yoshihiko Maehara ◽  
Sunao Moriguchi ◽  
Yoshihisa Sakaguchi ◽  
Yasunori Emi ◽  
Shunji Kohnoe ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Advanced Gastric Cancer ◽  
Curative Resection ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Non-curative gastrectomy for advanced gastric cancer does not result in additional risk of postoperative morbidity compared to curative gastrectomy

2020 ◽  
Vol 35 ◽  
pp. 126-131
Author(s):  
Emma C. Gertsen ◽  
Hylke J.F. Brenkman ◽  
Lucas Goense ◽  
Nadia Haj Mohammad ◽  
Bas L.A. Weusten ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Postoperative Morbidity ◽  
Curative Gastrectomy ◽  
Additional Risk

Evaluation of the effectiveness of adjuvant chemotherapy for locally advanced gastric cancer in real clinical practice

Pharmateca ◽  
2020 ◽  
Vol 7_2020 ◽  
pp. 41-45
Author(s):  
N.P. Belyak Belyak ◽  
R.V. Orlova Orlova ◽  
S.I. Kutukova Kutukova ◽  
N.V. Zhukova Zhukova ◽  
S.A. Borozdina Borozdina ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Practice ◽  
Adjuvant Chemotherapy ◽  
Advanced Gastric Cancer ◽  
Locally Advanced ◽  
Locally Advanced Gastric Cancer ◽  
Real Clinical Practice
Sign in / Sign up

Export Citation Format

Share Document